Quantamental Technologies LLC Raises Holdings in Intersect ENT Inc (XENT)

Quantamental Technologies LLC raised its stake in Intersect ENT Inc (NASDAQ:XENT) by 211.0% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,950 shares of the medical equipment provider’s stock after acquiring an additional 1,323 shares during the period. Quantamental Technologies LLC’s holdings in Intersect ENT were worth $63,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. NumerixS Investment Technologies Inc boosted its stake in Intersect ENT by 43.0% in the fourth quarter. NumerixS Investment Technologies Inc now owns 2,200 shares of the medical equipment provider’s stock valued at $60,000 after acquiring an additional 662 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Intersect ENT by 183.5% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,617 shares of the medical equipment provider’s stock worth $74,000 after buying an additional 1,694 shares during the period. Legal & General Group Plc boosted its position in shares of Intersect ENT by 14.8% during the fourth quarter. Legal & General Group Plc now owns 5,353 shares of the medical equipment provider’s stock worth $151,000 after buying an additional 690 shares during the period. Meeder Asset Management Inc. boosted its position in shares of Intersect ENT by 215.0% during the fourth quarter. Meeder Asset Management Inc. now owns 5,604 shares of the medical equipment provider’s stock worth $159,000 after buying an additional 3,825 shares during the period. Finally, BNP Paribas Arbitrage SA boosted its position in shares of Intersect ENT by 62,220.0% during the first quarter. BNP Paribas Arbitrage SA now owns 6,232 shares of the medical equipment provider’s stock worth $200,000 after buying an additional 6,222 shares during the period. Institutional investors own 95.98% of the company’s stock.

In related news, CFO Jeryl L. Hilleman sold 30,000 shares of the business’s stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $32.07, for a total transaction of $962,100.00. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Lisa D. Earnhardt sold 29,588 shares of the business’s stock in a transaction that occurred on Monday, April 15th. The stock was sold at an average price of $28.43, for a total value of $841,186.84. The disclosure for this sale can be found here. In the last three months, insiders have sold 106,246 shares of company stock worth $3,269,037. 5.90% of the stock is owned by corporate insiders.

XENT has been the subject of several analyst reports. Canaccord Genuity boosted their price objective on Intersect ENT from $36.00 to $40.00 and gave the stock a “buy” rating in a research report on Tuesday, February 26th. ValuEngine downgraded Intersect ENT from a “buy” rating to a “hold” rating in a research report on Monday, February 4th. BidaskClub downgraded Intersect ENT from a “hold” rating to a “sell” rating in a research report on Thursday, April 11th. BTIG Research reiterated a “hold” rating on shares of Intersect ENT in a research report on Tuesday, February 26th. Finally, Zacks Investment Research downgraded Intersect ENT from a “hold” rating to a “strong sell” rating in a research report on Friday, May 3rd. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and three have given a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $30.96.

Shares of NASDAQ XENT opened at $27.48 on Monday. The company has a market cap of $866.46 million, a PE ratio of -36.16 and a beta of 0.62. Intersect ENT Inc has a 12-month low of $24.39 and a 12-month high of $42.95.

Intersect ENT (NASDAQ:XENT) last announced its earnings results on Monday, May 6th. The medical equipment provider reported ($0.35) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.30) by ($0.05). Intersect ENT had a negative return on equity of 22.90% and a negative net margin of 24.99%. The firm had revenue of $26.70 million for the quarter, compared to the consensus estimate of $26.34 million. During the same period in the previous year, the firm earned ($0.21) EPS. Intersect ENT’s revenue for the quarter was up 8.1% on a year-over-year basis. Research analysts anticipate that Intersect ENT Inc will post -1.32 EPS for the current year.

TRADEMARK VIOLATION NOTICE: This article was first posted by Baseball Daily News and is the property of of Baseball Daily News. If you are reading this article on another publication, it was copied illegally and reposted in violation of US and international copyright laws. The original version of this article can be read at https://www.baseballdailydigest.com/news/2019/05/13/quantamental-technologies-llc-raises-holdings-in-intersect-ent-inc-xent.html.

Intersect ENT Company Profile

Intersect ENT, Inc, a drug delivery company, researches and develops products for the treatment of patients with ear, nose, and throat conditions in the United States. The company offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses.

See Also: Cost of Equity For A Business, Investors

Want to see what other hedge funds are holding XENT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intersect ENT Inc (NASDAQ:XENT).

Institutional Ownership by Quarter for Intersect ENT (NASDAQ:XENT)

Receive News & Ratings for Intersect ENT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT and related companies with MarketBeat.com's FREE daily email newsletter.